Skip to main content

PsA/SpA

Panel Presentation: Psoriatic Arthritis

Drs. Eric Ruderman, Alexis Ogdie, Jessica Walsh, and Jose Scher discuss the giselkumab trials, where IL-23 inhibitors fit in practice, ixekizumab withdrawal, and more that presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Pearls for Evaluating PSA patients: Dr. Guillermo Valenzuela

Dr. Valenzuela describes a variety of pearls for evaluating PSA patients at the 2019 ACR/ARP annual meeting in Atlanta. 

Tofacitinib as Monotherapy Following MTX Withdrawal in PsA: Dr. Eric Ruderman

Dr. Ruderman describes abstract #L14 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Ixekizimab Withdrawal in PSA: Dr. Eric Ruderman

Dr. Ruderman highlights abstract #1532 at the 2019 ACR/ARP annual meeting in Atlanta.

Comparison of Ixekizumab and Adalimumab in PsA: Dr. Olga Petryna

Dr. Petryna discusses abstract #L20 presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Depression in Psoriatic Arthritis: Dr. Olga Petryna

Dr. Petryna discusses the association between depression and rheumatologic conditions, including psoriatic arthritis, highlighting abstracts #178, #580#1490 and more.

Domain Strategy and Treatment in Psoriatic Arthritis: Dr. Elaine Husni

Dr. Elaine Husni reviews her talk on domain strategies in PsA at the 2019 ACR/ARP annual meeting in Atlanta.

Myosin Regulation May Contribute to Anti-TNF Therapy Response: Dr. Elaine Husni

Dr. Husni highlights abstract #1769 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.

Highlights of AS, Psoriatic Arthritis Studies: Dr. Lianne Gensler

Dr. Gensler reviews several studies on ankylosing spondylitis, non-radiographic axSpA, and psoriatic arthritis treatment presented at the 2019 ACR/ARP annual meeting in Atlanta. 

×